Biochemistry and Molecular Biology Journal
ISSN: 2471-8084

Open access Perspective

Determining the Endocrine Cancer Metabolism and Metabolomics

C. Justin Lee*

Department of Biochemistry, Sejong University, South Korea

INTRODUCTION

Clinical endocrinology demands a grasp of the mechanisms through which the endocrine system controls malignancies. The specific aetiology of endocrine malignancies is still unknown, which makes it difficult to distinguish between benign and malignant tumours and make an early diagnosis. Over the past few years, the fields of metabolomics and personalised medicine have seen significant advancements in the study of cancer. This systematic review focused on clinical metabolomics investigations used in the previous 12 years to diagnose endocrine tumours. Atomic magnetic resonance and Mass Spectrometry (MS), along with division techniques including gas chromatography and fluid chromatography, were largely used to lead disease metabolomics investigations.

DESCRIPTION

Our results showed that urine, serum/plasma, and tissue samples were employed in the majority of metabolomics investigations. The majority of studies focused on thyroid cancer, adrenal cancer, and pituitary cancer. Chemometrics and analytical hyphenated techniques are both effective approaches for identifying biomarkers in endocrine cancer and metabolic disorders. Despite decades of research, cancer remains one of the leading causes of mortality globally, putting a heavy burden not only on patients but also on their families and society at large. Endocrine malignancies are uncommon, heterogeneous tumours with a wide range of clinical characteristics, according to oncology experts. These tumours include those of the pancreas, pituitary, parathyroid and thyroid.

Endocrine tumours are frequently mistaken for benign tumours due to their propensity to produce hormones, which makes therapy more challenging. Researchers have also learned that malignancy can develop from metabolic alterations brought on by anomalies in hormone production and release from decades of study on endocrine cancers. Inhibiting transformed cell death and speeding proliferation are two potential impacts of hormones secreted by endocrine glands on cancer risk and progression. TSH, which is recognised as the thyroid's main regulator, can, for example, Thyroxine (T4) and triiodothyronine (T3), which are crucial for regulating the body's temperature, metabolism, and heart rate, are produced and released by the thyroid gland in response to the pituitary gland's secretion of TSH. Another example is pituitary tumours that produce a lot of the hormone adrenocorticotropic hormone (ACTH), which has a correlate. Thyroxine (T4) and triiodothyronine (T3), which are crucial for regulating the body's temperature, metabolism, and heart rate, are produced and released by the thyroid gland in response to the pituitary gland's secretion of TSH. Another example is pituitary tumours that produce a lot of the hormone adrenocorticotropic hormone (ACTH), which has a correlate.

There are currently no thorough and sufficient metabolomics studies that address the changes in metabolites in endocrine malignancies, and none of them are implemented in clinics, in part because it is difficult to understand the aetiology of these disorders. In essence, the variations in metabolite levels may be caused by the amount consumed or a change in how they are regulated as a result of genetics, nutrition, lifestyle, environment, stress, or age, among other things.

CONCLUSION

Furthermore, it is clear that the endocrine glands communicate with one another, regulate one another, and release hormones that have an impact on the body's metabolism during both positive and negative feedback. By conducting in-depth comprehensive metabolome analyses using a variety of matrices, screening other glands and hormone levels before each study of endocrine cancer, and reducing the impact of confounding factor.

Received:	03-October-2022	**Manuscript No:**	IPBMBJ-22-14927
Editor assigned:	05-October-2022	**PreQC No:**	IPBMBJ-22-14927 (PQ)
Reviewed:	19-October-2022	**QC No:**	IPBMBJ-22-14927
Revised:	22-August-2022	**Manuscript No:**	IPBMBJ-22-14927 (R)
Published:	29-August-2022	**DOI:**	10.36648/2471-8084-9.4.35

Corresponding author C. Justin Lee, Department of Biochemistry, Sejong University, South Korea, E-mail: cjl56@ibs.re.kr

Citation Lee CJ (2022) Determining the Endocrine Cancer Metabolism and Metabolomics. Biochem Mol Biol J. 9:35.